| Page 10 | Kisaco Research
 

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Brigham and Women’s Hospital

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Brigham and Women’s Hospital

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Brigham and Women’s Hospital
  • Exploring how housing, nutrition, identity, and income shape maternal outcomes.
  • Highlighting programs and solutions that integrate social support with clinical care.
  • Discussing actionable strategies in the clinical setting that embed accessibility and education into maternal health systems.
Nutrition and Food as Medicine
Maternal Health

Author:

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Brigham and Women’s Hospital
... read more

Nawal Nour

Chair & Director of Obstetrics & Gynecology
Brigham and Women’s Hospital
  • Concrete guidance on accessing non-dilutive and dilutive funding - what’s available, what’s working, and how to get it.
  • Strategies for founders and funders to navigate uncertainty and build investable, scalable ventures in women's health.
  • How women, as both innovators and investors, are transforming the funding ecosystem - and how to leverage that shift now.
Digital Health
Innovation and Investment

Author:

Lisa Marceau

CEO
Joyuus
... read more

Lisa Marceau

CEO
Joyuus
  • Sharing new clinical outcomes and how clinical trials are evolving.
  • Exploring the link between menopause, estrogen, and cognitive decline.
  • How biomarkers, digital tools, and lifestyle interventions can improve outcomes.
Brain Health
  • Sharing the role of technology and partnerships in the design & recruitment of studies.
  • Highlighting adaptive trial designs, decentralized models, and inclusive recruitment strategies.
  • Exploring how smarter trial design accelerates approval, reduces risk, and improves real-world outcomes.
Reproductive Health
Drug Development
Med Device
  • Demystifying product-market fit in the context of digital health, where clinical need, usability, and reimbursement must align.
  • Identifying key indicators—user adoption, engagement, and outcomes—that show readiness to scale.
  • Strategies for translating validated need into scalable, sustainable digital health solutions.
Innovation and Investment
  • Discuss strategies for trial design that account for hormonal fluctuations, comorbidities, and age-related variables unique to the menopausal transition.
  • Highlight regulatory, industry, and advocacy efforts that are pushing for menopause-specific representation in therapeutic areas beyond just women’s health.
  • Sharing advancements to educate clinical trial patients about menopause.
Menopause and Longevity
Drug Development
 

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences

Johan van Hylckama

CSO
Freya Biosciences